scholarly journals ACCESS TO TREATMENT IN HIV PREVENTION TRIALS: PERSPECTIVES FROM A SOUTH AFRICAN COMMUNITY

2009 ◽  
Vol 10 (2) ◽  
pp. 78-87 ◽  
Author(s):  
NICOLA BARSDORF ◽  
SUZANNE MAMAN ◽  
NANCY KASS ◽  
CATHERINE SLACK
Keyword(s):  
Hiv Prevention ◽  
South African ◽  
Access To Treatment ◽  
African Community ◽  
Prevention Trials

scholarly journals Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Maurine D. Miner ◽  
Linda-Gail Bekker ◽  
Tamara Kredo ◽  
Niresh Bhagwandin ◽  
Lawrence Corey ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Hiv Prevention ◽  
South African ◽  
Medical Research Council ◽  
Standard Of Care ◽  
Hiv Vaccine ◽  
Middle Income ◽  
Hiv Vaccine Trials ◽  
Vaccine Trials ◽  
Prevention Trials

AbstractA cornerstone of HIV prevention clinical trials is providing a combination prevention package to all trial participants. The elements included in that standard of care (SoC) package evolve as new prevention modalities are developed. Pre-exposure prophylaxis (PrEP) was recommended by the World Health Organization for persons at high risk of acquiring HIV, but not all countries immediately adopted those recommendations. The South African Medical Research Council (SAMRC) convened a summit to discuss issues relating to SoC and PrEP in HIV prevention clinical trials taking place in lower- to middle-income countries (LMIC). Policymakers, regulators, ethicists, experts in law, researchers, representatives of advocacy groups, and the HIV Vaccine Trials Network (HVTN) presented a framework within which SoC principles could be articulated. A group of subject matter experts presented on the regulatory, ethical, scientific, and historic framework of SoC in clinical trials, focusing on PrEP in South Africa. Summit participants discussed how and when to include new HIV treatment and prevention practices into existing clinical guidelines and trial protocols, as well as the opportunities for and challenges to scaling up interventions. The summit addressed challenges to PrEP provision, such as inconsistent efficacy amongst different populations and various biological, virological, and immunological explanations for this heterogeneity. Advocates and community members propagated the urgent need for accessible interventions that could avert HIV infection. The meeting recommended supporting access to PrEP in HIV prevention trials by (1) developing PrEP access plans for HIV vaccine trials, (2) creating a PrEP fund that would supply PrEP to sites conducting HIV prevention trials via a central procurement mechanism, and (3) supporting the safety monitoring of PrEP. This report summarizes the presentations and discussions from the summit in order to highlight the importance of SoC in HIV prevention clinical trials.

scholarly journals Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial

2020 ◽  
Author(s):  
Ivana Beesham ◽  
Renee Heffron ◽  
Shannon Evans ◽  
Jared M. Baeten ◽  
Jenni Smit ◽  
...  
Keyword(s):  
South Africa ◽  
Hiv Prevention ◽  
South African ◽  
Medical Research Council ◽  
Trial Site ◽  
Study Staff ◽  
Prevention Trials ◽  
Post Trial ◽  
Exposure Prophylaxis ◽  
First Time

Abstract HIV endpoint-driven clinical trials in Africa enroll women who are at heightened risk of acquiring HIV. In 2017, the South African Medical Research Council recommended the provision of oral pre-exposure prophylaxis (PrEP) in HIV prevention trials, at which time the Evidence for Contraceptive Options and HIV Outcomes trial was ongoing and began to provide PrEP on-site at some trial sites. We interviewed 132 women who initiated PrEP on-site at the Durban, South Africa trial site to explore PrEP use, and conducted phone-based interviews 4–6 months post-trial exit to explore post-trial PrEP access. PrEP uptake was high (42.6%). Among women initiating PrEP on-site, 87.9% felt at risk of acquiring HIV. Most women (> 90%) heard of PrEP for the first time from study staff and three-quarters who initiated PrEP on-site continued at trial-exit. PrEP use declined post-trial exit with more than 50% of women discontinuing PrEP, and barriers relating to access emerged.

Standard of care for social harms in HIV prevention trials: A South African perspective

2019 ◽  
Vol 20 (4) ◽  
pp. 194-199
Author(s):  
Takshita Sookan ◽  
Ganzamungu Zihindula ◽  
Douglas Wassenaar
Keyword(s):  
Hiv Prevention ◽  
South African ◽  
Standard Of Care ◽  
African Perspective ◽  
Prevention Trials

scholarly journals Meeting Report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017

2020 ◽  
Author(s):  
Maurine Miner ◽  
Linda-Gail Bekker ◽  
Tamara Kredo ◽  
Niresh Bhagwandin ◽  
Lawrence Corey ◽  
...  
Keyword(s):  
Hiv Prevention ◽  
Medical Research ◽  
South African ◽  
Medical Research Council ◽  
Standard Of Care ◽  
Hiv Vaccine ◽  
Hiv Vaccine Trials ◽  
Treatment And Prevention ◽  
Vaccine Trials ◽  
Prevention Trials

Introduction: The South African Medical Research Council (SAMRC) convened a summit to discuss issues relating to standard of care (SoC) in HIV prevention clinical trials, both for treatment and prevention of disease. Policymakers, regulators, ethicists, experts in the law (as it pertains to medical research), researchers, representatives of advocacy groups, and the HIV Vaccine Trials Network (HVTN) presented a framework within which SoC principles could be articulated. Discussion: Summit participants discussed how and when to include new modalities of HIV treatment and prevention into existing clinical practice guidelines, and by extension in clinical trial protocols. Participants involved in the execution of care and the scale-up of new interventions, in particular, the roll out of pre-exposure prophylaxis (PrEP), presented the opportunities for and challenges to scaling up interventions, and their experience with demonstration projects of PrEP. Advocates and community members propagated the need to make interventions that could avert HIV infection available as soon as possible. Experts in evidence-based guideline development discussed the nuances in evaluating evidence for policy and the mechanisms for getting medicines on the Essential Medicines List in South Africa. Given the variability in clinical trial efficacy of PrEP amongst different populations, scientists and statisticians discussed the various biological, virological and immunological reasons for this heterogeneity. Conclusions: Input was given as to the impact of introducing PrEP in other HIV prevention trials, and the considerations for the design of both antiretroviral (ARV)-based and non-ARV based HIV prevention trials. The meeting recommended supporting access to PrEP in HIV prevention trials by 1) developing PrEP access plans for HIV vaccine trials; 2) creating a PrEP fund that would supply PrEP to sites conducting HIV prevention trials via a central procurement mechanism; and 3) support the safety monitoring of PrEP.

scholarly journals High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study

2017 ◽  
Vol 72 (2) ◽  
pp. 168-172 ◽  
Author(s):  
Alain Vandormael ◽  
Tulio de Oliveira ◽  
Frank Tanser ◽  
Till Bärnighausen ◽  
Joshua T Herbeck
Keyword(s):  
Hiv Testing ◽  
South African ◽  
Hiv Infections ◽  
Population Based ◽  
Hiv Positive ◽  
Aids Epidemic ◽  
Undiagnosed Hiv ◽  
African Community ◽  
Repeat Hiv Testing ◽  
High Level

BackgroundUndiagnosed HIV infections could undermine efforts to reverse the global AIDS epidemic by 2030. In this study, we estimated the percentage of HIV-positive persons who remain undiagnosed within a hyperendemic South African community.MethodsThe data come from a population-based surveillance system located in the Umkhanyakude district of the northern KwaZulu-Natal province, South Africa. We annually tested 38 661 adults for HIV between 2005 and 2016. Using the HIV-positive test results of 12 039 (31%) participants, we then back-calculated the incidence of infection and derived the number of undiagnosed cases from this result.ResultsThe percentage of undiagnosed HIV cases decreased from 29.3% in 2005 to 15.8% in 2011. During this period, however, approximately 50% of the participants refused to test for HIV, which lengthened the average time from infection to diagnosis. Consequently, the percentage of undiagnosed HIV cases reversed direction and steadily increased from 16.1% to 18.9% over the 2012–2016 period.ConclusionsResults from this hyperendemic South African setting show that the HIV testing rate is low, with long infection times, and an unsatisfactorily high percentage of undiagnosed cases. A high level of repeat HIV testing is needed to minimise the time from infection to diagnosis if the global AIDS epidemic is to be reversed within the next two decades.

scholarly journals P3.380 Baseline Results of a Cluster-Randomised Trial Assessing the Effectiveness of Sport-Based HIV Prevention in South African Schools

2013 ◽  
Vol 89 (Suppl 1) ◽  
pp. A268.1-A268
Author(s):  
Z A Kaufman ◽  
E B Kaufman ◽  
S Dringus ◽  
H A Weiss ◽  
S Delany-Moretlwe ◽  
...  
Keyword(s):  
Hiv Prevention ◽  
South African ◽  
Randomised Trial ◽  
Cluster Randomised Trial ◽  
Cluster Randomised
Sign in / Sign up

Export Citation Format

Share Document